Time to read
less than
1 minute
Read so far

Study to investigate CA7S metabolite’s role as a novel T2DM therapy

Wed, 01/13/2021 - 09:35
Posted in:

Researchers at Brigham and Women’s Hospital have been awarded a US$3.3M National Institutes of Health Grant to evaluate the CA7S metabolite as a novel therapy for type 2 diabetes; uncover how CA7S production is regulated by the gut microbiome; and determine the contribution of CA7S to type 2 diabetes remission, following bariatric surgery.

Dr Eric Sheu, Associate Surgeon, Division of General and Gastrointestinal Surgery, Associate Program Director, Advanced Minimally Invasive Surgery Fellowship at Brigham’s and Assistant Professor of Surgery, Harvard Medical School and colleagues were awarded the grant for the study, ‘A microbiome-dependent bile acid metabolite improves type 2 diabetes’. The study is funded by the NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), whose mission is to conduct and support medical research and research training and to disseminate science-based information on diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic, and hematologic diseases, to improve people’s health and quality of life.

Sheu’sclinical practice focuses on bariatric, foregut and hernia surgery. He directs an NIH R01-funded laboratory that investigates how changes in immunology and metabolism triggered by bariatric surgery leads to resolution of type 2 diabetes. His research has been supported by numerous societies and philanthropic institutions, including the American Surgical Association (ASA), the Blavatnik Biomedical Accelerator, the Quadrangle Fund for Advancing and Seeding Translational Research (Q-FASTR) and Harvard Catalyst.